Related Experiment Video
Updated: May 23, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Iloperidone for the treatment of schizophrenia: an updated clinical review
1Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612-7327, USA. pweiden@psych.uic.edu
Abstract:
Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism. Iloperidone was approved by the FDA in May 2009 for the treatment of schizophrenia. This review is a comprehensive synthesis of the history and clinical trials data leading up to approval, and evaluates iloperidone within the clinical context of how it compares with other available antipsychotics.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antipsychotic Drugs: Typical and Atypical Agents
Antidepressant Drugs: MAOIs and Other Agents